The race to lead America’s surgical robotics market is heating up — and the next battleground is gynecology. On April 29, 2026, Cambridge-based CMR Surgical submitted a 510(k) premarket notification to the U.S. FDA, seeking clearance to expand its Versius Plus™ Surgical Robotic System into benign gynecologic procedures including total hysterectomy, oophorectomy, and salpingectomy. It’s a targeted but significant move that could reshape how American women access minimally invasive robotic surgery — and put CMR one step closer to its goal of becoming a major U.S. surgical robotics contender.
CMR Surgical’s U.S. Gynecology Push
Cambridge-based CMR Surgical made a significant regulatory move on April 29, 2026, submitting a 510(k) premarket notification to the FDA seeking clearance for its Versius Plus™ Surgical Robotic System to be used in benign gynecology procedures — including total hysterectomy, oophorectomy, and salpingectomy. The submission builds on the system’s existing FDA clearance for cholecystectomy and marks a deliberate expansion into one of the most common surgical specialties in the United States.
Why Gynecology Is the Next Big Battleground for Surgical Robots
The global surgical robotics market is crowded, but gynecology represents a particularly high-opportunity frontier. In the U.S. alone, hundreds of thousands of gynecologic procedures are performed annually, many of which could benefit from the precision and minimally invasive approach that robotic-assisted surgery enables. CMR notes that gynecologic procedures already represent a large proportion of all Versius cases recorded globally — underscoring that clinical demand is already proven; the regulatory gap is what needs closing.
“It is an exciting time for CMR as we seek to expand into gynecology in the U.S. and accelerate access to robotic-assisted surgery with Versius Plus in the largest surgical robotic market in the world,” said Massimiliano Colella, CEO of CMR Surgical. The company is positioning itself as a challenger to the established players in the American market, leveraging its track record of over 45,000 patients treated globally with the Versius system.
What Makes Versius Plus Different
CMR’s system has always distinguished itself through modularity and surgeon flexibility. Versius Plus allows surgeons to use familiar laparoscopic port placement while accessing the precision of fully wristed instrumentation compatible with 5mm ports. The platform also features advanced 3D visualization on a digitally integrated robotic platform — combining the tactile familiarity of traditional laparoscopy with the enhanced dexterity that robotics provides.
Unlike some competing systems that require significant redesign of operating room workflows, Versius has been designed with adaptability in mind. This philosophy appears to be paying off: outside the U.S., Versius is already the second most utilized surgical robotic system globally, a notable achievement for a company that only recently entered the American market.
A Responsible, Evidence-Based U.S. Expansion
CMR’s approach to regulatory expansion has been measured and evidence-driven. Rather than pursuing a broad initial clearance and then attempting to expand indications, the company has built its U.S. story incrementally — starting with a confirmed indication (cholecystectomy), accumulating clinical experience, and now pursuing gynecology with the backing of global case data. The company has also committed to engaging with the American College of Obstetricians and Gynecologists community at its upcoming Annual Meeting, signaling intent to win over not just regulators but the clinical community.
What This Means for the Broader Surgical Robotics Landscape
CMR’s gynecology submission is the latest signal that the U.S. surgical robotics market is entering a new phase of competition. While Intuitive Surgical’s da Vinci system has dominated for years, a wave of challengers — including CMR, Medtronic with its Hugo system, and Johnson & Johnson’s Ottava platform — are actively competing for hospital contracts and surgeon loyalty. For healthcare systems evaluating robotic platforms, this competition is healthy: it drives innovation, brings down costs, and accelerates adoption of minimally invasive surgical techniques.
For patients, the expanding regulatory clearance of systems like Versius Plus means robotic-assisted surgery may become more accessible across more procedure types — particularly in specialties like gynecology where the benefits of precision and minimal invasiveness are well established but access has been limited by technology availability.
With 45,000 patients already treated worldwide and a clear regulatory roadmap, CMR Surgical is making a disciplined, evidence-backed case for why Versius Plus should become a standard feature of American operating rooms. The FDA’s decision will be a pivotal moment — for CMR and for the broader trajectory of robotic surgery access in the U.S.
